Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dysbiosis of the microbiome correlates with many neurological disorders, yet very little is known about the chemistry that controls the production of neuromodulatory molecules by gut microbes. Here, we found that an enzyme glutamate decarboxylase (GAD) of a gut microbe forms multiple neuromodulatory molecules such as γ-aminobutyric acid (GABA), hypotaurine, taurine, homotaurine, and β-alanine. We evolved GAD and doubled its taurine productivity. Additionally, we increased its specificity toward the substrate L-glutamate. Here, we provide a chemical strategy via which the GAD activity could be fine-tuned. In future, this strategy could be used to modulate the production of neuromodulatory molecules by gut microbes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013497PMC
http://dx.doi.org/10.1016/j.isci.2025.112289DOI Listing

Publication Analysis

Top Keywords

neuromodulatory molecules
16
molecules gut
12
glutamate decarboxylase
8
production neuromodulatory
8
gut microbes
8
synthesis versatile
4
neuromodulatory
4
versatile neuromodulatory
4
molecules
4
gut
4

Similar Publications

Background: Epilepsy is a chronic and complex brain disorder characterized by frequent seizures, cognitive impairments, neuroinflammation, oxidative stress, and imbalances in neurotransmitters. Developing an effective therapeutic intervention to target these pathological interventions remains a challenge. Trimetazidine (TMZ), the most commonly known anti-ischemic agent, has emerged as a promising candidate for its role in epilepsy due to its diverse mechanisms of action.

View Article and Find Full Text PDF

The glymphatic system as a therapeutic target: TMS-induced modulation in older adults.

Front Aging Neurosci

July 2025

Brain Imaging and TMS Laboratory, Department of Psychology, University of Arizona, Tucson, AZ, United States.

While repetitive transcranial magnetic stimulation (rTMS) is a promising neuromodulatory intervention for cognitive impairment, its effects on the glymphatic system remain unexplored in clinical populations. Deficient glymphatic clearance has emerged as a central feature of neurodegenerative disease, which can now be assessed with specialized diffusion magnetic resonance imaging techniques. This study examines changes in the diffusion tensor imaging analysis along the perivascular space (DTI-ALPS) index following theta-burst stimulation (TBS) in older adults with mild cognitive impairment (MCI).

View Article and Find Full Text PDF

Exploration of the potential neurotransmitter or neuromodulator-like properties of harmine: evidence from synthesis to synaptic modulation.

Front Pharmacol

July 2025

The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Background: The discovery of new neurotransmitters is crucial for the in-depth understanding of neural signal transmission, neurological disorders, and relevant treatment strategies. Emerging evidence has indicated that harmine is an important endogenous compound, and its level is closely related to different physiological and disease states. Inspired by this, we propose a hypothesis that harmine may be a potential neurotransmitter or neuromodulator and display neurotransmitter or neuromodulator-like properties.

View Article and Find Full Text PDF

N6-methyladenosine RNA methylation, an essential post-transcriptional modification, dynamically regulates RNA metabolism and plays a crucial role in neuronal function. Growing evidence suggests that dysregulated N6-methyladenosine modification contributes to the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. However, the precise mechanisms by which N6-methyladenosine modification influences these conditions remain unclear.

View Article and Find Full Text PDF

Background: Stroke remains a leading cause of disability and death worldwide. While reperfusion therapies such as tissue plasminogen activator and mechanical thrombectomy have significantly improved stroke management, their effectiveness is limited by ischemia/reperfusion injury, which disrupts the blood-brain barrier (BBB), increases neuroinflammation, and exacerbates secondary neuronal damage. Consequently, there is an urgent need for adjunctive therapies that specifically target these secondary injury mechanisms.

View Article and Find Full Text PDF